Results 1 to 10 of about 18,708 (185)
International Journal of Immunopathology and Pharmacology, 2023 Objectives: Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disorder. The proportion of elderly individuals at risk for AD and cardiovascular problems increases by raising life expectancy.
Abdallah Salah El-din Hussein +3 more
doaj +2 more sources
Molecules, 2021 The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with cardioprotective properties.
Pema Raj +6 more
doaj +1 more source
Scientific Reports, 2021 Left ventricular remodeling due to pressure overload is associated with poor prognosis. Sacubitril/valsartan is the first-in-class Angiotensin Receptor Neprilysin Inhibitor and has been demonstrated to have superior beneficial effects in the settings of ...
Xiaofei Li +4 more
doaj +1 more source
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada +2 more
openaire +2 more sources
Cardiovascular Diabetology, 2022 Background Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.
Magnus O. Wijkman +14 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2023 IntroductionIn 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from ...
Pei Yang +7 more
doaj +1 more source
Frontiers in Public Health, 2022 BackgroundSacubitril-valsartan was recommended for heart failure (HF) and proven cost-effective in HF. Recently, sacubitril-valsartan has been recommended to treat hypertension by the Chinese expert consensus. The cost utility of sacubitril-valsartan for
Yake Lou +4 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Background: The episode of acute decompensated heart failure (ADHF) is the main cause of hospitalization for heart failure (HF). Sacubitril–valsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF.
Tianyang Hu, Yiting Liu, Yake Lou
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy.
Christof Burgdorf +4 more
doaj +1 more source
, 2015 Valsartan is an antihypertensive drug which selectively inhibits angiotensin receptor type II. Generally, valsartan is available as film-coated tablets. This review summarizes thermal analysis, spectroscopy characteristics (UV, IR, MS, and NMR), polymorphism forms, impurities, and related compounds of valsartan.
Febry, Ardiana +2 more
openaire +2 more sources